# US 2019/0316101 A1 · Methods and compositions for genetically manipulating genes and cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0316101 A1
- Document ID: US20190316101A1
- Status: Published application
- Kind: A1
- Application number: 16/039,150
- Filed: 2018-07-18
- Published: 2019-10-17
- Earliest claimed: 2017-07-18
- Applicants: Howard Hughes Medical Institute
- Inventors: Tzumin Lee; Jorge Garcia Marques; Hui-Min Chen
- Web page: https://patentgrep.com/patent/US20190316101A1

## CPC

- C12N 9/222: {Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2330/51: Specially adapted vectors
- C12N 2510/00: Genetically modified cells
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

This disclosure provides methods and compositions for genetically manipulating genes and cells.

## Claims

### Claim 1

A nucleic acid switch cassette comprising a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences.

### Claim 2 (depends on 1)

The switch cassette of claim 1, wherein the target nucleic acid sequence in the nucleic acid switch cassette is complementary to a spacer sequence of at least one guideRNA.

### Claim 3 (depends on 1)

The switch cassette of claim 1, wherein the first and second direct repeats are each from about 3 bp in length to about 1000 bp in length.

### Claim 4 (depends on 1)

The switch cassette of claim 1, wherein the first and second direct repeats are not identical.

### Claim 5 (depends on 1)

The switch cassette of claim 1, wherein the first and second direct repeats have at least 80% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 95% sequence identity, or at least 99% sequence identity to one another.

### Claim 6 (depends on 1)

The switch cassette of claim 1, wherein the nucleic acid switch cassette is engineered into a desired nucleic acid sequence.

### Claim 7 (depends on 1)

The switch cassette of claim 1, wherein the switch cassette is an expression-on switch.

### Claim 8 (depends on 1)

The switch cassette of claim 1, wherein the switch cassette is an expression-off switch.

### Claim 9

A method, comprising
engineering a nucleic acid switch cassette into at least one desired nucleic acid sequence, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences;
exposing the at least one desired nucleic acid comprising the nucleic acid switch cassette to a CRISPR system, wherein the CRISPR system comprises at least one guide RNA (gRNA) and a nuclease enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the nuclease enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds;
exposing the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides; and
determining the on-off status of the nucleic acid switch cassette of the desired nucleic acid sequence based on a phenotype.

### Claim 10 (depends on 9)

The method of claim 9, wherein the desired nucleic acid sequence is an open reading frame.

### Claim 11 (depends on 9)

The method of claim 9, wherein the desired nucleic acid sequence comprises a plurality of open reading frames, each comprising a different switch cassette.

### Claim 12 (depends on 9)

The method of claim 9, wherein the desired nucleic acid sequence is a guide RNA (gRNA) sequence.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gRNA sequence is comprised within an open reading frame.

### Claim 14 (depends on 9)

The method of claim 9, wherein the desired nucleic acid sequence comprises a plurality of gRNA sequences, each comprising a different switch cassette.

### Claim 15 (depends on 9)

The method of claim 9, wherein the desired nucleic acid sequence is a promoter sequence.

### Claim 16 (depends on 9)

The method of claim 9, wherein the switch cassette is an expression-on switch.

### Claim 17 (depends on 9)

The method of claim 9, wherein the switch cassette is an expression-off switch.

### Claim 18

A method, comprising
providing a protein-encoding nucleic acid sequence comprising a nucleic acid switch cassette, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences and disrupts the protein-encoding nucleic acid sequence such that a functional protein is not produced;
contacting the disrupted protein-encoding nucleic acid sequence comprising the nucleic acid switch cassette to a CRISPR/Cas9 system, wherein the CRISPR/Cas9 system comprises at least one guide RNA (gRNA) and a Cas9 enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the Cas9 enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds; and
contacting the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides;
thereby causing excision of the nucleic acid switch cassette from the disrupted protein-encoding nucleic acid sequence and restoring production of a functional protein.

### Claim 19

A method, comprising
providing a protein-encoding nucleic acid sequence comprising a nucleic acid switch cassette, wherein the nucleic acid switch cassette comprises a target nucleic acid sequence flanked by first and second direct repeat nucleic acid sequences and does not disrupt the protein-encoding nucleic acid sequence such that a functional protein is produced;
contacting the protein-encoding nucleic acid sequence comprising the nucleic acid switch cassette to a CRISPR/Cas9 system, wherein the CRISPR/Cas9 system comprises at least one guide RNA (gRNA) and a Cas9 enzyme, wherein a spacer sequence in the at least one gRNA is complementary to the target nucleic acid sequence in the nucleic acid switch cassette, wherein, under appropriate conditions, the Cas9 enzyme cleaves the target nucleic acid sequence to which the spacer sequence in the at least one gRNA binds; and
contacting the cleaved target nucleic acid sequence to single strand annealing (SSA) polypeptides or nucleic acids encoding SSA polypeptides;
thereby causing excision of the nucleic acid switch cassette from the protein-encoding nucleic acid sequence, which results in disruption of the protein-encoding nucleic acid sequence such that a functional protein is not produced.

### Claim 20

A kit, comprising:
at least one cloning vector with direct repeats and a MCS between the direct repeats;
at least one gRNA construct designed to accommodate a target sequence within the spacer sequence; and/or
at least one CRISPR construct comprising a MCS.

### Claim 21

A kit, comprising:
a cloning vector with at least one switch cassette upstream from a MCS; and
a plurality of cloning vectors, each comprising a different gRNA, wherein at least one gRNA matches a target sequence.

### Claim 22 (depends on 21)

The kit of claim 21, further comprising a MCS for cloning in a promoter of interest in each vector.

### Claim 23

A kit, comprising:
a cloning vector with an ON switch cassette upstream from a MCS;
a cloning vector with an OFF switch cassette upstream from a MCS;
a cloning vector comprising a nucleic acid sequence encoding a Cas9 enzyme downstream from a MCS; and
a cloning vector comprising a first gRNA in the cascade, downstream from a MCS.

### Claim 24

A nucleic acid construct comprising, in the 5′ to 3′ direction, a first exon, a disruptor exon and a second exon, wherein the first exon and the second exon together encode a functional moiety, wherein the first splice acceptor sequence comprises a nucleic acid sequence that is complementary to a spacer sequence of a first guide RNA (gRNA).

### Claim 25 (depends on 24)

The nucleic acid construct of claim 24, wherein the first exon and the second exon together encode a detectable polypeptide.

### Claim 26 (depends on 24)

The nucleic acid construct of claim 24, wherein the first exon and the second exon together encode a second guide RNA.

### Claim 27 (depends on 24)

The nucleic acid construct of claim 24, wherein the cassette is an expression-on cassette.

### Claim 28 (depends on 24)

The nucleic acid construct of claim 24, wherein the cassette is an expression-off cassette.

### Claim 29 (depends on 24)

A method comprising:
exposing the nucleic acid construct of claim 24 to a CRISPR system comprising a gRNA and a CRISPR system nuclease.

### Claim 30

A transgenic organism comprising:
a first transgenic construct comprising, in the 5′ to 3′ direction, a promoter, at least one guide RNA (gRNA), and a first detectable polypeptide;
wherein a germ line of the first transgenic organism comprises a CRISPR system nuclease.

### Claim 31 (depends on 30)

A method, comprising:
contacting the transgenic organism of claim 30 with a guide RNA (gRNA);
breeding the gRNA-contacted transgenic organism to produce a first progeny having a first phenotype.
